Japanese Journal of Cancer Research · 1998 · 17 citations · 38 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyCancer MetabolismMalignant NeoplasmsNicotinamide Adenine Dinucleotide MetabolismWeight Loss Reduction
When a cachexigenic subclone (clone 20) of murine colon 26 adenocarcinoma was transplanted into female BALB/c mice, hepatic NNMT activity continued to increase until death in proportion to progressive carcass weight loss, a marker of cancer cachexia. On the other hand, noncachexigenic subclone (clone 5)-transplanted mice showed neither increase of NNMT activity nor carcass weight loss. Among cytostatic fluorinated pyrimidines, 5'-dFUrd could inhibit the increase of NNMT activity and prevent weight loss in mice bearing clone 20. On the other hand, 2'-dFUrd did not show these effects. 5-FUra and Tegafur inhibited the increase of NNMT activity at higher concentrations. These findings suggest that the levels of hepatic NNMT activity are closely associated with the degree of weight loss, and they appear to be a useful marker of cancer cachexia.
38
Prognostic effect of weight loss prior tochemotherapy in cancer patients
William D. DeWys, Colin B. Begg, Philip T. Lavin et al. · The American Journal of Medicine · 1980 · 2.4K citations
Evidence for the involvement of interleukin 6 in experimental cancer cachexia.
Gideon Strassmann, M Fong, J S Kenney et al. · Journal of Clinical Investigation · 1992 · 656 citations · Full text
Life Sciences, Immunology, Oncology +14
Characterization of a cancer cachectic factor
Penio Todorov, Peter Cariuk, Trudi McDevitt et al. · Nature · 1996 · 437 citations
Medicine, Cancer Biology, Oncology +10